A randomized, double-blind clinical study on blood pressure reduction and blood lipid profile amelioration on treatment with Ankascin 568 

A randomized, placebo-controlled clinical study was designed to assess the efficacy of RYR in reducing plasma cholesterol and triglycerides. A total of 60 patients were randomized to receive two RYR capsules a day or placebos, for eight weeks. Each capsule contained 110 mg of RYR, including 3 mg of monascin and 1.5 mg of ankaflavin. Statistical analyses focused on the 21 patients who completed the study. In the RYR group, plasma LDL-C was 15% lower by four weeks of treatment and remained stable to the end of the study. Triglycerides decreased by 25% and total cholesterol dropped by 12%. 

References:

Chen C-L, Tseng J-H, Pan T-M, Hsiao S-H. A Randomized, Double-Blind Clinical Study on Blood Pressure Reduction and Blood Lipid Profile Amelioration on Treatment with Ankascin 568. Chin J Physiol. 2017;60(3):158-165. doi:https://dx.doi.org/10.4077/CJP.2017.BAF452.